Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Nephrology (Carlton) ; 20(4): 266-72, 2015 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-25581532

RESUMEN

AIM: Renal ischaemia-reperfusion (I/R) injury, a primary cause of acute renal failure, can induce high morbidity and mortality. This study aimed to explore the effect of erythropoietin on renal I/R injury and its underlying mechanism. METHODS: Fifty male Sprague-Dawley rats were randomly allocated to three groups (n = 10): the sham group, the renal ischaemia-reperfusion-saline (IRI) group, and the IRI+-Erythropoietin (EPO) group. Erythropoietin (250, 500, 1000 U/kg) was intraperitoneally injected 30 min before inducing I/R. Renal I/R injury were induced by clamping the left renal artery for 30 min followed by reperfusion, along with a contralateral nephrectomy. Renal function and histological damage were determined after 24 h reperfusion. The expression of pro-inflammatory cytokines interleukin-6 (IL-6), interleukin-1 ß (IL-1ß), and tumour necrosis factor-α (TNF-α) in the serum and renal tissue were evaluated by enzyme linked immunosorbent assay (ELISA) and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Further, the effects of erythropoietin on PI3K/Akt signalling, erythropoietin receptor (EPOR) and nuclear factor (NF)-κB activation were measured by Western blotting. RESULTS: Erythropoietin pretreatment can significantly decrease the level of renal dysfunction in a dose-dependent manner, attenuated the renal histological changes, the expression of TNF-α, IL-1ß, and IL-6, the levels of reactive oxygen species (ROS) production and NF-κB p65 phosphorylation in renal tissue upon IRI. Moreover, erythropoietin pretreatment could further activate the PI3K/Akt signalling and induced EPOR activity. CONCLUSIONS: Erythropoietin pretreatment could attenuate renal I/R injury by suppressing inflammation, which was associated with activating PI3K/Akt signalling though EPOR activation. Our findings suggest that erythropoietin may be a novel practical strategy to prevent renal I/R injury.


Asunto(s)
Lesión Renal Aguda/prevención & control , Antiinflamatorios/administración & dosificación , Eritropoyetina/administración & dosificación , Riñón/efectos de los fármacos , Fosfatidilinositol 3-Quinasa/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Daño por Reperfusión/prevención & control , Transducción de Señal/efectos de los fármacos , Lesión Renal Aguda/sangre , Lesión Renal Aguda/enzimología , Lesión Renal Aguda/patología , Animales , Biomarcadores/sangre , Citoprotección , Modelos Animales de Enfermedad , Activación Enzimática , Mediadores de Inflamación/sangre , Interleucina-1beta/sangre , Interleucina-6/sangre , Riñón/enzimología , Riñón/patología , Masculino , Fosforilación , Ratas Sprague-Dawley , Especies Reactivas de Oxígeno/metabolismo , Receptores de Eritropoyetina/agonistas , Receptores de Eritropoyetina/metabolismo , Daño por Reperfusión/sangre , Daño por Reperfusión/enzimología , Daño por Reperfusión/patología , Factor de Transcripción ReIA/metabolismo , Factor de Necrosis Tumoral alfa/sangre
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...